Want to see TSE:BIOV full AI Analyst Report?
Top Page
BioVaxys Technology
(BIOV)
Select Model
Select Model
Rating:29Underperform
Price Target:―
Action:N/A
Date:04/29/25
BioVaxys Technology faces severe financial challenges, with no revenue and reliance on external financing, which heavily impacts its overall score. Technical analysis indicates weak momentum and a bearish trend, while the negative valuation metrics highlight the risks involved. However, the company is taking steps towards financial management and exploring new market opportunities, which could improve its future prospects.
BioVaxys Technology (BIOV) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$2.04M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.24
Shares Outstanding44,094,670
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-7.14
Price to Sales (P/S)0.00
P/FCF Ratio-4.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BioVaxys Technology Business Overview & Revenue Model
Company Description
BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of vaccine platforms designed to combat both viral infections and cancer. The company's pipeline includes BVX-0320, a single-strain vaccine for SAR...
How the Company Makes Money
BioVaxys Technology generates revenue primarily through the development and commercialization of its vaccine candidates. The company aims to monetize its proprietary haptenized vaccines through licensing agreements, partnerships with pharmaceutica...
BioVaxys Technology Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Oct 2024 | Apr 2024 | Jan 2023 | Jan 2022 | Jan 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -4.91M | -3.95M | -7.69M | 3.58M | -6.42M | -1.09M |
| Net Income | -6.04M | -3.95M | -7.69M | -11.73M | -6.46M | -1.17M |
Balance Sheet | ||||||
| Total Assets | 1.39M | 1.30M | 113.48K | 865.56K | 8.50M | 10.46M |
| Cash, Cash Equivalents and Short-Term Investments | 4.08K | 211.81K | 977.00 | 141.90K | 593.12K | 2.42M |
| Total Debt | 133.72K | 68.08K | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.03M | 3.22M | 3.49M | 1.64M | 326.86K | 900.09K |
| Stockholders Equity | -3.64M | -1.92M | -3.37M | -773.53K | 8.18M | 9.56M |
Cash Flow | ||||||
| Free Cash Flow | -2.97M | -2.92M | -1.05M | -1.57M | -5.29M | -1.23M |
| Operating Cash Flow | -2.97M | -1.86M | -1.05M | -1.57M | -5.29M | -1.23M |
| Investing Cash Flow | 0.00 | -1.06M | 0.00 | 0.00 | 0.00 | 61.36K |
| Financing Cash Flow | 2.48M | 3.13M | 917.10K | 1.11M | 3.44M | 3.35M |
BioVaxys Technology Technical Analysis
Positive
0.07
Price Trends
0.07
Negative
0.07
Positive
0.11
Negative
Market Momentum
<0.01
Positive
54.04
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BIOV, the sentiment is Positive. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 54.04 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BIOV.
BioVaxys Technology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | C$31.05M | -1.84 | -360.29% | ― | ― | -33.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$43.32M | -0.35 | -147.92% | ― | ― | 85.31% | |
48 Neutral | C$597.60K | 1.45 | 34.52% | ― | ― | ― | |
46 Neutral | C$61.82M | -21.65 | 74.79% | ― | ― | -15.53% | |
42 Neutral | C$37.89M | -4.39 | -1661.38% | ― | ― | -40.15% | |
29 Underperform | C$2.04M | -0.91 | 69.89% | ― | ― | ― |
* Healthcare Sector Average
TSE:BIOV
BioVaxys Technology
0.07
-0.22
-75.86%
TSE:ARCH
Arch Biopartners
0.92
-0.73
-44.24%
TSE:MDNA
Medicenna Therapeutics Corp
0.41
-0.59
-59.09%
TSE:BCT
BriaCell Therapeutics
5.92
-6.62
-52.79%
TSE:VXL
Vaxil Bio
0.15
-0.06
-27.50%
TSE:DTC
Defence Therapeutics
0.50
-0.20
-28.57%
BioVaxys Technology Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
BioVaxys and SpayVac Expand License to Target Aquaculture Market
Positive
Apr 22, 2025
BioVaxys Technology Corp. and SpayVac for Wildlife, Inc. have expanded their license agreement to include commercial aquaculture, targeting the farm-raised fish market with their no-booster fertility-control vaccines. This expansion presents a sig...
Delistings and Listing ChangesPrivate Placements and FinancingBusiness Operations and StrategyRegulatory Filings and Compliance
BioVaxys Technology Corp. Revokes Cease Trade Order and Settles Debt
Positive
Apr 10, 2025
BioVaxys Technology Corp. announced the revocation of a management cease trade order by the British Columbia Securities Commission following the completion of its required financial filings. Additionally, the company has settled a debt of $60,000 ...
Private Placements and FinancingBusiness Operations and Strategy
BioVaxys Technology Corp. Announces Debt Settlement to Optimize Financial Operations
Positive
Apr 1, 2025
BioVaxys Technology Corp. has announced a debt settlement agreement with THECCSGROUP, where it will issue 1,200,000 common shares to settle a $60,000 debt. This strategic move aims to preserve the company’s cash for working capital, reflecti...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
BioVaxys Technology Corp. Updates on Management Cease Trade Order Status
Neutral
Mar 18, 2025
BioVaxys Technology Corp. has announced a bi-weekly update regarding a management cease trade order (MCTO) due to delays in filing its audited annual financial statements. The company is working with its auditor to complete the filings by March 30...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
BioVaxys Technology Corp. Receives Management Cease Trade Order Amid Filing Delays
Negative
Mar 4, 2025
BioVaxys Technology Corp. has been granted a management cease trade order (MCTO) by the British Columbia Securities Commission due to a delay in filing its audited annual financial statements and related documents. The delay is attributed to the r...
Private Placements and FinancingBusiness Operations and Strategy
BioVaxys Settles Debt and Closes Final Private Placement Tranche
Positive
Feb 19, 2025
BioVaxys Technology Corp. has announced a debt settlement agreement with consultants by issuing shares to preserve cash for working capital. Additionally, the company extended its private placement closing date and closed its final tranche, raisin...
M&A TransactionsFinancial DisclosuresRegulatory Filings and Compliance
BioVaxys Faces Potential Filing Delay Amid Recent Acquisitions
Neutral
Feb 14, 2025
BioVaxys Technology Corp. has announced a potential delay in filing its annual financial statements due to the complexities involved in auditing its recent acquisition of intellectual property and assets from IMV Inc. The company is proactively se...
Private Placements and Financing
BioVaxys Extends Private Placement Closing Date to February 14, 2025
Positive
Feb 8, 2025
BioVaxys Technology Corp. has announced an extension to the closing date of its non-brokered private placement offering, originally set for February 7, 2025, and now extended to February 14, 2025. This extension aims to allow additional investors ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.